Top

Published in:

01-03-2013 | Original Article

Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy

Authors: Nicolò Pecorelli, Marco Braga, Claudio Doglioni, Gianpaolo Balzano, Michele Reni, Stefano Cereda, Luca Albarello, Renato Castoldi, Giovanni Capretti, Valerio Di Carlo

Published in: Journal of Gastrointestinal Surgery | Issue 3/2013

Abstract

Background

Preoperative chemotherapy (PCHT) has recently been proposed also in patients with resectable pancreatic adenocarcinoma. Few data are currently available on the impact of PCHT on short-term postoperative outcome after pancreatic resection. The objective of this study is to assess the impact of PCHT on pancreatic structure and short-term outcome after surgical resection.

Methods

Fifty consecutive patients successfully underwent resection after PCHT. Each patient was matched with two control patients with pancreatic adenocarcinoma selected from our prospective electronic database. Match criteria were age (±3 years), gender, American Society of Anesthesiologist score, type of resection, pancreatic duct diameter (±1 mm), and tumor size (±5 mm). Primary endpoint was morbidity rate. Secondary endpoints were pancreatic parenchymal structure, mortality rate, and length of hospital stay (LOS).

Results

Both degree of fibrosis and fatty infiltration of the pancreas were similar in the two groups. Overall morbidity rate was 48.0 % in the PCHT group vs. 54.0 % in the control group (p = 0.37). Pancreatic fistula rate was 18.0 % in the PCHT group vs. 25.0 % in the control group (p = 0.41). Mortality was 4.0 % in the PCHT group vs. 2.0 % in the control group (p = 0.60). Mean LOS (days) was 12.7 in the PCHT group vs. 12.4 in the control group (p = 0.74). There was no difference in resection margin status, while the rate of patients without nodal involvement was higher in the PCHT group (46.0 vs. 23.0 %, p = 0.004).

Conclusion

PCHT did not induce significant structural changes in pancreatic parenchyma and did not adversely affect short-term outcome after surgery.

Reni M, Cereda S, Balzano G, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2009; 64(6): 1253–1259.PubMedCrossRef

Katz MH, Pisters PW, Evans DB, et al.: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206:833–846.PubMedCrossRef

Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 Apr 20;7(4):e1000267.

Raut CP, Evans DB, Crane CH, et al. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin North Am 2004;13:639–661CrossRef

Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14: 2088–2096PubMedCrossRef

Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1–7PubMedCrossRef

Buie WD, MacLean AR, Attard JA, et al. Neoadjuvant chemoradiation increases the risk of pelvic sepsis after radical excision of rectal cancer. Dis Colon Rectum 2005; 48(10): 1868–74.PubMedCrossRef

Tsikitis VL, Larson DW, Poola VP, et al. Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience. J Am Coll Surg. 2009; 209(1): 114–118PubMedCrossRef

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11–20.PubMedCrossRef

10.

Sobin LH, Wittekind CH (eds). Exocrine pancreas. In: AJCC cancer staging manual, 6th edn. New York: Springer; 2002; 157.

11.

Pecorelli N, Balzano G, Capretti G et al. Effect of surgeon volume on outcome following pancreaticoduodenectomy in a high-volume hospital. J Gastrointest Surg 2012; 16(3): 518–523.PubMedCrossRef

12.

Bozzetti F, Braga M, Gianotti L, et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 2001; 358: 1487–1492.PubMedCrossRef

13.

Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138:8–13.PubMedCrossRef

14.

Balzano G, Zerbi A, Braga M, et al. Fast-track recovery programme after pancreatico-duodenectomy reduces delayed gastric emptying. Br J Surg 2008; 95:1387–1393.PubMedCrossRef

15.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–213PubMedCrossRef

16.

DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006; 244:931–937.PubMedCrossRef

17.

Wellner UF, Kayser G, Lapshyn H, et al. A simple scoring system based on clinical factors related to pancreatic texture predicts postoperative pancreatic fistula preoperatively. HPB (Oxford) 2010; 12(10): 696–702CrossRef

18.

Mathur A, Pitt HA, Marine M, et al. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg 2007, 246:1058–1064.PubMedCrossRef

19.

Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10–15.PubMedCrossRef

20.

Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92:547–556.PubMedCrossRef

21.

Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200–1210PubMedCrossRef

22.

Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with Gemcitabine vs observation in patients undergoing curative intent resection of pancreatic cancer. A randomized controlled trial. JAMA 2007; 297: 267–277PubMedCrossRef

23.

Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008; 248:1014–1022PubMedCrossRef

24.

Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on the outcome of pancreaticoduodenectomy in Italy. Br J Surg 2008; 95: 357–362.PubMedCrossRef

25.

Hartman DJ, Krasinskas AM. Assessing Treatment Effect in Pancreatic Cancer. Arch Pathol Lab Med 2012; 136(1): 100–109.PubMedCrossRef

26.

Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010; 17(7):1794–801.PubMedCrossRef

27.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351:1731–1740PubMedCrossRef

28.

Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035–46.PubMedCrossRef

Title: Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy
Authors: Nicolò Pecorelli
Marco Braga
Claudio Doglioni
Gianpaolo Balzano
Michele Reni
Stefano Cereda
Luca Albarello
Renato Castoldi
Giovanni Capretti
Valerio Di Carlo
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 3/2013
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-012-2063-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

Characteristics of Extremely Early-Onset Pouchitis after Proctocolectomy with Ileal Pouch–Anal Anastomosis

Defining Treatment and Outcomes of Hepaticojejunostomy Failure Following Pancreaticoduodenectomy

Surgical Strategies in Patients with Advanced Hilar Cholangiocarcinoma (Klatskin Tumor)

The Use of Over the Scope Clip (OTSC) Device for Sleeve Gastrectomy Leak

Appendicitis and Benign Appendiceal Mucocele Presenting as Large Bowel Obstruction

Epidermoid Cyst of the Spleen